Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emune Plus is a nutraceutical or Ayurvedic proprietary medicine developed by Parnasa Mediworld. It is typically formulated as a combination of herbal extracts, most notably *Carica papaya* (papaya leaf) and *Tinospora cordifolia* (Giloy). The product is primarily indicated as an immunomodulator and for the management of thrombocytopenia (low platelet count), often associated with viral infections such as Dengue fever. *Carica papaya* extract is believed to stimulate platelet production by enhancing the activity of enzymes involved in megakaryocyte formation and upregulating the ALOX12 gene. *Tinospora cordifolia* contributes to the formulation's therapeutic profile through its immunomodulatory properties, which include the stimulation of macrophage activity. Although previously listed in the developer's pipeline or product catalog, recent information suggests the product may have been discontinued or is no longer actively marketed by the company.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Emune Plus.